A newly described stage of a lymph node-like structure seen in liver tumors after ... and receives research funds from Abbvie. Ho has received patent royalties from Rodeo/Amgen and grants or ...

Patient advocates are hoping for change under new director Michelle Tarver, while industry groups hope she will build on ...

Patient advocates are hoping for change under new director Michelle Tarver, while industry groups look to build on former ...

According to Stock Rover* in the trailing 1-year, the Dividend Kings have returned +22.1% (blue line) compared to +37.1% for the S&P 500 Index benchmark (red line), as seen in the chart below ...

Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

Analyst Carter Gould of Barclays maintained a Buy rating on AbbVie (ABBV – Research Report), retaining the price target of $212.00. Carter Gould has given his Buy rating due to a combination of ...

JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...

Neuroscience is a key area of focus for AbbVie. In addition to emraclidine, through the Cerevel acquisition AbbVie gained a neuroscience pipeline of multiple clinical-stage and preclinical ...

A splashy recent acquisition by the company might not be panning out. Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary ...